GoodRx Holdings, Inc.
A digital health platform providing discount solutions for prescription medicines
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying GoodRx stock with a target price of $8.51, indicating potential growth.
Financial Health
GoodRx is performing well with strong revenue and profits, but cash flow shows some fluctuations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GDRX
Walgreens Restructuring Explained: Investment Shifts
Following its acquisition by Sycamore Partners, Walgreens has gone private and split into five companies. This theme explores the investment opportunities created by the newly independent healthcare and retail entities.
Published: September 2, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: June 17, 2025
Explore BasketDigital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Usage and reach
GoodRx’s monthly active users and partnerships drive traffic and monetisation opportunities, though user growth can be cyclical and competitive.
Revenue mix matters
Income from advertising, transactions and subscriptions provides diversification, but changes in pharmacy pricing or regulation could affect margins.
Policy and competition
Regulatory decisions and rival digital-health offerings can reshape the outlook; investors should weigh potential upside against execution and regulatory risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Microsoft Corporation
Microsoft is a tech company that develops, manufactures, licenses, supports, and sells computer software, consumer electronics, personal computers, and related services.
Alphabet Inc. - Class C Shares
Alphabet Inc. - Class C Shares is a technology company that offers web-based services, digital media, cloud computing and other services.
Alphabet Inc (Google)
Alphabet - A is a technology company that offers web-based services, digital media, cloud computing and other services.
